Regulation of genetic engineering
The regulation of genetic engineering begins before the experiment has started with approval processes, through to protocols that must be followed in the laboratory and finally the conditions under which the resultant product may be released. These regulations vary from country to country, particularly when it comes to the release of any genetically modified organism. Europe does not have a single policy but a patchwork of policies at international, Community, Member State and local levels.
The development of a regulatory framework concerning genetic engineering began in 1975, at Asilomar, California. The first use of Recombinant DNA (rDNA) technology had just been successfully accomplished by Stanley Cohen and Herbert Boyer two years previously and the scientific community recognized that as well as benefits this technology could also pose some risks. The Asilomar meeting recommended a set of guidelines regarding the cautious use of recombinant technology and any products resulting from that technology. The Asilomar recommendations were voluntary, but in 1976 the US National Institute of Health (NIH) formed a rDNA advisory committee. This was followed by other regulatory offices (the United States Department of Agriculture (USDA), Environmental Protection Agency (EPA) and Food and Drug Administration (FDA)), effectively making all rDNA research tightly regulated in the USA.
In 1982 the Organization for Economic Co-operation and Development (OECD) released a report into the potential hazards of releasing genetically modified organisms into the environment as the first transgenic plants were being developed. As the technology improved and genetically organisms moved from model organisms to potential commercial products the USA established a committee at the Office of Science and Technology (OSTP) to develop mechanisms to regulate the developing technology. In 1986 the OSTP assigned regulatory approval of genetically modified plants in the US to the USDA, FDA and EPA.
The Cartagena Protocol on Biosafety was adopted on 29 January 2000 and entered into force on 11 September 2003. It is an international treaty that governs the transfer, handling, and use of genetically modified (GM) organisms. It is focussed on movement of GMOs between countries and has been called a de facto trade agreement. One hundred and fifty-seven countries are members of the Protocol and many use it as a reference point for their own regulations.
The European Union first introduced laws requiring GMO's to be labelled in 1997. In 2013, Connecticut became the first state to enact a labeling law in the USA, although it would not take effect until other states followed suit.
Approval to conduct experiments
Institutions that conduct certain types of scientific research must obtain permission from government authorities and ethical committees before they conduct any experiments. Universities and research institutes generally have a special committee that is responsible for approving any experiments that involve genetic engineering. Many experiments also need permission from a national regulatory group. Most countries have exempt dealings for genetically modified organisms (GMOs) that only pose a low risk. These include systems using standard laboratory strains as the hosts, recombinant DNA that does not code for a vertebrate toxin or is not derived from a micro-organism that can cause disease in humans. Exempt dealings usually do not require approval from the national regulator. GMOs that pose a low risk if certain management practices are complied with are classified as notifiable low risk dealings. The final classification is for any uses of GMOs that do not meet the previous criteria. These are known as licensed dealings and include cloning any genes that code for vertebrate toxins or using hosts that are capable of causing disease in humans. Licensed dealings require the approval of the national regulator.
In the laboratory
Work with exempt GMOs do not need to be carried out in certified laboratories. All others must be contained in a Physical Containment level 1 (PC1) or Physical Containment level 2 (PC2) laboratories. Laboratory work with GMOs classified as low risk, which include knockout mice, are carried out in PC1 lab. This is the case for modifications that do not confer an advantage to the animal or doesn't secrete any infectious agents. If a laboratory strain that is used isn't covered by exempt dealings or the inserted DNA could code for a pathogenic gene, it must be carried out in a PC2 laboratory.
The approaches taken by governments to assess and manage the risks associated with the use of genetic engineering technology and the development and release of genetically modified organisms (GMOs) vary from country to country, with some of the most marked differences occurring between the United States and Europe. The U.S. regulatory policy is governed by the Coordinated Framework for Regulation of Biotechnology The policy has three tenets: "(1) U.S. policy would focus on the product of genetic modification (GM) techniques, not the process itself, (2) only regulation grounded in verifiable scientific risks would be tolerated, and (3) GM products are on a continuum with existing products and, therefore, existing statutes are sufficient to review the products." European Union by contrast enacted regulatory laws in 2003 that provided possibly the most stringent GMO regulations in the world. All GMOs, along with irradiated food, are considered "new food" and subject to extensive, case-by-case, science-based food evaluation by the European Food Safety Authority (EFSA). The criteria for authorization fall in four broad categories: "safety," "freedom of choice," "labelling," and "traceability."
The European Union has heavily contrasted its regulations and restrictions regarding genetic engineering compared to those of the United States. The European Parliament's Committee on the Environmental, Public Health, and Consumer Protection pushed forward and adopted a "safety first" principle regarding the case of GMOs, calling for any negative health consequences from GMOs to be held liable. On the other hand, the United States still takes on a less hands-on approach to the regulation of GMOs, with the FDA and USDA only looking over pesticide and plant health facets of GMOs. Despite the overall global increase in the production in GMOs, the European Union has still stalled GMOs fully integrating into its food supply. This has definitely affected various countries, including the United States, when trading with the EU.
However, although the European Union has had relatively strict regulations regarding the genetically modified food, Europe is now allowing newer versions of modified maize and other agricultural produce. Also, the level of GMO acceptance in the European Union varies across its countries with Spain and Portugal being more permissive of GMOs than France and the Nordic population.
For a genetically modified organism to be approved for release in the U.S., it must be assessed under the Plant Protection Act by the Animal and Plant Health Inspection Service (APHIS) agency within the US Department of Agriculture (USDA) and may also be assessed by the Food and Drug Administration (FDA) and the Environmental protection agency (EPA), depending on the intended use of the organism. The USDA evaluate the plants potential to become weeds, the FDA reviews plants that could enter or alter the food supply, and the EPA regulates genetically modified plants with pesticide properties, as well as agrochemical residues. In Europe the EFSA reports to the European Commission who then draft a proposal for granting or refusing the authorisation. This proposal is submitted to the Section on GM Food and Feed of the Standing Committee on the Food Chain and Animal Health and if accepted it will be adopted by the EC or passed on to the Council of Agricultural Ministers. Once in the Council it has three months to reach a qualified majority for or against the proposal, if no majority is reached the proposal is passed back to the EC who will then adopt the proposal. However, even after authorization, individual EU member states can ban individual varieties under a 'safeguard clause' if there are "justifiable reasons" that the variety may cause harm to humans or the environment. The member state must then supply sufficient evidence that this is the case. The Commission is obliged to investigate these cases and either overturn the original registrations or request the country to withdraw its temporary restriction.
The level of regulation in other countries lies in between Europe and the United States. Common Market for Eastern and Southern Africa (COMASA) is responsible for assessing the safety of GMOs in most of Africa, although the final decision lies with each individual country. India and China are the two largest producers of genetically modified products in Asia. The Office of Agricultural Genetic Engineering Biosafety Administration (OAGEBA) is responsible for regulation in China, while in India it is the Institutional Biosafety Committee (IBSC), Review Committee on Genetic Manipulation (RCGM) and Genetic Engineering Approval Committee (GEAC). Brazil and Argentina are the 2nd and 3rd largest producers of GM food. In Argentine assessment of GM products for release is provided by the National Agricultural Biotechnology Advisory Committee (environmental impact), the National Service of Health and Agrifood Quality (food safety) and the National Agribusiness Direction (effect on trade), with the final decision made by the Secretariat of Agriculture, Livestock, Fishery and Food. In Brazil the National Biosafety Technical Commission is responsible for assessing environmental and food safety and prepares guidelines for transport, importation and field experiments involving GM products, while the Council of Ministers evaluates the commercial and economical issues with release. Health Canada and the Canadian Food Inspection Agency are responsible for evaluating the safety and nutritional value of genetically modified foods released in Canada. License applications for the release of all genetically modified organisms in Australia is overseen by the Office of the Gene Technology Regulator, while regulation is provided by the Therapeutic Goods Administration for GM medicines or Food Standards Australia New Zealand for GM food. The individual state governments can then assess the impact of release on markets and trade and apply further legislation to control approved genetically modified products.
One of the key issues concerning regulators is whether GM products should be labeled. Labeling can be mandatory up to a threshold GM content level (which varies between countries) or voluntary. A study investigating voluntary labeling in South Africa found that 31% of products labeled as GMO-free had a GM content above 1.0%. In Canada and the United States labeling of GM food is voluntary, while in Europe all food (including processed food) or feed which contains greater than 0.9% of approved GMOs must be labelled. Japan, Malaysia, New Zealand, and Australia require labeling so consumers can exercise choice between foods that have genetically modified, conventional or organic origins.
The Cartagena Protocol sets the requirements for the international trade of GMO's between countries that are signatories to it. Any shipments contain geneticially modified organisms that are intended to be used as feed, food or for processing must be identified and a list of the transgenic events be available.
Public knowledge of genetic engineering can effect the regulation of it. There's information asymmetry in this field. Consumers who know more about bio engineering products are more susceptible to resisting whereas those that don't have as much information on this subject are more inclined to buy GM products. The Food Policy Institute surveyed consumers on their knowledge of genetically modified organisms (GMOs). Over 60% of surveyors reported that they know little to nothing about genetically modified (GM) products. Over 50% of these consumers had no knowledge that GM products are being sold to consumers in supermarkets. When surveying people with a stronger background in science(i.e nursing students), knowledge on GMOs were surprisingly low—about 30% correctly identified crops that were GM products.
Genetically modified animals
Transgenic animals have genetically modified DNA. Animals are different from plants in a variety of ways—biology, life cycles, or potential environmental impacts. GM plants and animals were being developed around the same time, but due to the complexity of their biology and inefficiency with laboratory equipment use, their appearance in the market was delayed.
There are six categories that genetically engineered (GE) animals are approved for:
- Use for biomedical research. Smaller mammalians can be used as models in scientific research to represent other mammals.
- Used to develop innovative kinds of fish for environmental monitoring.
- Used to produce proteins that humans lack. This can be for therapeutic use, for example, treatment of diseases in other mammals.
- Use for investigating and finding cures for diseases. Can be used for introducing disease resistance in GM breeds.
- Used to create manufacturing products for industry use.
- Used for improving food quality.
- Kathy Wilson Peacock (2010). Biotechnology and Genetic Engineering. Infobase Publishing.
- Berg P, Baltimore D, Boyer HW, Cohen SN, Davis RW, Hogness DS, Nathans D, Roblin R, Watson JD, Weissman S, Zinder ND (1974). "Letter: Potential biohazards of recombinant DNA molecules" (PDF). Science. 185 (4148): 303. doi:10.1126/science.185.4148.303. PMID 4600381.
- Berg, P., Baltimore, D., Brenner, S., Roblin, R. O., and Singer, M. F. (1975). "Summary Statement of the Asilomar Conference on Recombinant DNA Molecules". Proc. Natl. Acad. Sci. USA. 72 (6): 1981–1984. doi:10.1073/pnas.72.6.1981. PMC . PMID 806076.
- Hutt, P.B. (1978). "Research on recombinant DNA molecules: the regulatory issues". South Calif Law Rev. 51 (6): 1435–50. PMID 11661661.
- McHughen A, Smyth S (2008). "US regulatory system for genetically modified [genetically modified organism (GMO), rDNA or transgenic] crop cultivars". Plant biotechnology journal. 6 (1): 2–12. doi:10.1111/j.1467-7652.2007.00300.x. PMID 17956539.
- Bull, A.T., Holt, G. and Lilly, M.D. (1982). Biotechnology : international trends and perspectives (PDF). Paris: Organisation for Economic Co-operation and Development.
- U.S. Office of Science and Technology Policy (1986). "Coordinated framework for regulation of biotechnology" (PDF). Fed Regist. 51 (123): 23302–50. PMID 11655807.
- "About the Protocol". The Biosafety Clearing-House (BCH).
- Redick, T.P. (2007). "The Cartagena Protocol on biosafety: Precautionary priority in biotech crop approvals and containment of commodities shipments, 2007". Colorado Journal of International Environmental Law and Policy. 18: 51–116.
- "AgBioForum 13(3): Implications of Import Regulations and Information Requirements under the Cartagena Protocol on Biosafety for GM Commodities in Kenya".
- Gruère, Colin A. Carter and Guillaume P. (2003-12-15). "Mandatory Labeling of Genetically Modified Foods: Does it Really Provide Consumer Choice?". www.agbioforum.org. Retrieved 2016-01-21.
- Strom, Stephanie (2013-06-03). "Connecticut Approves Qualified Genetic Labeling". The New York Times. ISSN 0362-4331. Retrieved 2016-01-21.
- United States Regulatory Agencies Unified Biotechnology Website
- Emily Marden, Risk and Regulation: U.S. Regulatory Policy on Genetically Modified Food and Agriculture, 44 B.C.L. Rev. 733 (2003)
- John Davison (2010)"GM plants: Science, politics and EC regulations" Plant Science 178(2):94–98 
- GMO Compass: The European Regulatory System. Retrieved 28 July 2012.
- Endres, A. Bryan (2000-01-01). ""GMO" Genetically Modified Organism or Gigantic Monetary Obligation? The Liability Schemes for GMO Damage in The United States and the European Union". ResearchGate. 22. ISSN 0277-5417.
- Jensen, Henning; Jensen, Hans; Gylling (15 September 2009). "Adoption of GM Food Crop Varieties in the European Union" (PDF). Institute of Food and Resource Economics, University of Copenhagen. Retrieved 15 November 2016.
- Mahgoub, Salah (2015). Genetically Modified Foods: Basics, Applications, and Controversy. Taylor & Francis Group. p. 9. ISBN 9781482242812.
- Costa-Font, Montserrat; Gil, José M.; Traill, W. Bruce (2008-04-01). "Consumer acceptance, valuation of and attitudes towards genetically modified food: Review and implications for food policy". Food Policy. 33 (2): 99–111. doi:10.1016/j.foodpol.2007.07.002.
- FDA page for GM Food
- "Guide to U.S. Regulation of Genetically Modified Food and Agricultural Biotechnology Products" (PDF). The Pew Initiative on Food and Biotechnology. Washington, DC: The Pew Charitable Trusts. 2001. Retrieved 2012-06-02.
- "Health and Consumers: Food and feed safety." (under "What are the National safeguard measures?") Link. Retrieved 28 July 2012.
- Transgenic harvest Editorial, Nature 467 , pages 633–634, 7 October 2010, doi:10.1038/467633b. Retrieved 9 November 2010
- "ISAAA Brief 37-2007 - Slides & Tables > ISAAA.org".
- "AgBioForum 5(4): Agricultural Biotechnology Development and Policy in China".
- "TNAU Agritech Portal :: Bio Technology".
- "Slides & Tables : Global Status of Commercialized Biotech/GM Crops: 2010 - ISAAA Brief 42-2010 - ISAAA.org".
- BASF presentation
- Canadian Food Inspection Agency - Regulating Agricultural Biotechnology
- http://www.thecanadianencyclopedia.com/articles/genetically-modified-foods. Genetically Modified Food.
- Agriculture - Department of Primary Industries
- "Welcome to the Office of the Gene Technology Regulator Website". Office of the Gene Technology Regulator. Retrieved 25 March 2011.
- Gerda M. Botha and Christopher D. Viljoen (2009) "South Africa: A case study for voluntary GM labelling" Food Chemistry 112(4):1060–1064 
- "The Regulation of Genetically Modified Food".
- Northwestern.edu Northwestern Journal of Technology and Intellectual Property Paper on: "Consumer Protection" Consumer Strategies and the European Market in Genetically Modified Foods
- Gatto, Kelsey (2015). "Consumer Perception of Genetically Modified Organisms and Sources of Information". Advances in nutrition. 6 (February): 842–851.
- Murray, J.D (2016). "Opinion: A new paradigm for regulating genetically engineered animals that are used as food". Proceedings of the National Academy of Sciences. 113 (13): 3410–3413. doi:10.1073/pnas.1602474113. PMC . PMID 27035930.
- Vàzquez-Salat, Núria (2013). "Are good ideas enough? The impact of socio-economic and regulatory factors on GMO commercialisation". Biological Research. 46 (4): 317–322. doi:10.4067/S0716-97602013000400002. PMID 24510133.
- Jagadeesan, Premananh (2015). "Transgenic and cloned animals in the food chain - are we prepared to tackle it?". Journal of the Science of Food and Agriculture. 95 (14): 2779–2782. doi:10.1002/jsfa.7205. PMID 25857482.